{
  "individual_results": [
    {
      "question": "What is the mechanism of action for Cetuximab and which receptor does it target?",
      "gt_answer": "Cetuximab is an epidermal growth factor receptor (EGFR) binding fragment antigen-binding (FAB), targeting the EGFR in humans. Its mechanism of action involves binding to the N-terminal portion of human EGFR.",
      "system_answer": "Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR).\n\nCetuximab works by binding to the extracellular domain of the EGFR, thereby inhibiting the receptor",
      "gt_sources": [
        "None",
        "drugbank-targets"
      ],
      "system_sources": [
        "General scientific knowledge and literature on Cetuximab. Specific document sources were not found in the retrieved passages."
      ],
      "metrics": {
        "rouge1": 0.4666666666666667,
        "rouge2": 0.3103448275862069,
        "rougeL": 0.39999999999999997,
        "string_similarity": 0.32,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 14.461257934570312,
        "llm_correctness": 0.8,
        "inference_cost": 0.64904,
        "inference_tokens": 73806,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.64904,
        "total_tokens": 73806,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.6480400000000001,
            "tokens": 63806,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.6480400000000001,
            "tokens": 63806,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What are the components of Etanercept and how is it produced?",
      "gt_answer": "Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system.",
      "system_answer": "Information about the components and production of Etanercept could not be found in the retrieved passages.\n\nThe passages retrieved were related to other drugs and their interactions or production processes, not Etanercept.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [
        "No relevant sources found in the retrieved passages."
      ],
      "metrics": {
        "rouge1": 0.1728395061728395,
        "rouge2": 0.0,
        "rougeL": 0.09876543209876544,
        "string_similarity": 0.01855287569573284,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 18.469494104385376,
        "llm_correctness": 0.0,
        "inference_cost": 1.39484,
        "inference_tokens": 148396,
        "api_calls": 13,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 1.39484,
        "total_tokens": 148396,
        "api_calls": 13,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 1.3938400000000002,
            "tokens": 138396,
            "calls": 12
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 1.3938400000000002,
            "tokens": 138396,
            "calls": 12
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "Which drug is associated with the FDA label titled \"FDA Approved Drug Products: Lupron Depot (leuprolide acetate) depot suspension\"?",
      "gt_answer": "The drug associated with the FDA label titled \"FDA Approved Drug Products: Lupron Depot (leuprolide acetate) depot suspension\" is linked to the parent key DB00007.",
      "system_answer": "Information about the FDA label for Lupron Depot (leuprolide acetate) depot suspension could not be found.\n\nThe search did not yield relevant information about the FDA label for Lupron Depot. The retrieved passages discussed unrelated drugs such as leflunomide and ropinirole.",
      "gt_sources": [
        "None",
        "drugbank-drugs_links"
      ],
      "system_sources": [
        "No relevant sources found in the current search."
      ],
      "metrics": {
        "rouge1": 0.3939393939393939,
        "rouge2": 0.21875,
        "rougeL": 0.30303030303030304,
        "string_similarity": 0.4009111617312073,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 13.356827974319458,
        "llm_correctness": 0.0,
        "inference_cost": 0.3933,
        "inference_tokens": 48364,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.3933,
        "total_tokens": 48364,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.3923,
            "tokens": 38364,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.3923,
            "tokens": 38364,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "For which drug is Prothrombin a known target, and what is the organism associated with this target?",
      "gt_answer": "Prothrombin is a known target for the drug Lepirudin, and the organism associated with this target is humans.",
      "system_answer": "Prothrombin is a known target for several drugs, and the associated organism is Humans.\n\nThe drugs that target Prothrombin include Lepirudin, Bivalirudin, Drotrecogin alfa, Coagulation Factor IX (Recombinant), Menadione, Argatroban, Proflavine, Zinc, and many others. The organism associated with Prothrombin as a target is Humans.",
      "gt_sources": [
        "None",
        "drugbank-targets"
      ],
      "system_sources": [
        "drugbank_drug",
        "drugbank_targets"
      ],
      "metrics": {
        "rouge1": 0.5396825396825397,
        "rouge2": 0.39344262295081966,
        "rougeL": 0.5396825396825397,
        "string_similarity": 0.4909090909090909,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 14.5953049659729,
        "llm_correctness": 0.8,
        "inference_cost": 0.9136,
        "inference_tokens": 100344,
        "api_calls": 8,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.9136,
        "total_tokens": 100344,
        "api_calls": 8,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.9126,
            "tokens": 90344,
            "calls": 7
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.9126,
            "tokens": 90344,
            "calls": 7
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the state of the drug Dornase alfa, and what is its primary therapeutic use?",
      "gt_answer": "Dornase alfa is in a liquid state. Its primary therapeutic use involves the enzymatic breakdown of extracellular DNA to reduce sputum viscosity and viscoelasticity in individuals with cystic fibrosis.",
      "system_answer": "Information about Dornase alfa is not available in the current dataset.\n\nThe retrieved passages do not contain information about Dornase alfa. The passages retrieved are about other drugs such as Didanosine, Darunavir, Deferasirox, Dasatinib, and Donepezil.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [
        "No relevant sources found in the current dataset."
      ],
      "metrics": {
        "rouge1": 0.18461538461538463,
        "rouge2": 0.06349206349206349,
        "rougeL": 0.18461538461538463,
        "string_similarity": 0.02188183807439825,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 15.114099025726318,
        "llm_correctness": 0.0,
        "inference_cost": 1.2422000000000002,
        "inference_tokens": 133262,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 1.2422000000000002,
        "total_tokens": 133262,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 1.2412,
            "tokens": 123262,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 1.2412,
            "tokens": 123262,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the mechanism of action of Cetuximab?",
      "gt_answer": "Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) on human cells. By targeting this receptor, Cetuximab inhibits the growth and survival of tumor cells that rely on the EGFR signaling pathway. This mechanism is confirmed by its known action on the EGFR in humans.",
      "system_answer": "Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR).\n\nCetuximab works by binding to the extracellular domain of the EGFR, thereby blocking the binding of natural ligands such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha). This inhibition prevents the activation of the receptor and subsequent downstream signaling pathways that promote cell proliferation and survival. As a result, Cetuximab can inhibit tumor growth and induce apoptosis in cancer cells that overexpress EGFR.",
      "gt_sources": [
        "None",
        "drugbank-targets"
      ],
      "system_sources": [
        "General knowledge and scientific literature on Cetuximab."
      ],
      "metrics": {
        "rouge1": 0.5538461538461539,
        "rouge2": 0.265625,
        "rougeL": 0.3384615384615385,
        "string_similarity": 0.2727272727272727,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 10.950609922409058,
        "llm_correctness": 1.0,
        "inference_cost": 0.56233,
        "inference_tokens": 65207,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.56233,
        "total_tokens": 65207,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.56133,
            "tokens": 55207,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.56133,
            "tokens": 55207,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the target organism for Lepirudin and what is its known action?",
      "gt_answer": "The target organism for Lepirudin is humans, and its known action is to inhibit prothrombin, a key protein in the blood coagulation process.",
      "system_answer": "Information about Lepirudin not found\n\nThe search did not yield any relevant information about Lepirudin, its target organism, or its known action. The retrieved passages were about other drugs and their mechanisms.",
      "gt_sources": [
        "None",
        "drugbank-targets"
      ],
      "system_sources": [
        "No relevant sources found"
      ],
      "metrics": {
        "rouge1": 0.3272727272727273,
        "rouge2": 0.11320754716981131,
        "rougeL": 0.2545454545454546,
        "string_similarity": 0.3436619718309859,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 11.75826096534729,
        "llm_correctness": 0.0,
        "inference_cost": 1.12873,
        "inference_tokens": 122071,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 1.12873,
        "total_tokens": 122071,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 1.1277300000000001,
            "tokens": 112071,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 1.1277300000000001,
            "tokens": 112071,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the main therapeutic use of Dornase alfa, and how does it achieve this effect?",
      "gt_answer": "Dornase alfa is primarily used in individuals with cystic fibrosis. It works by enzymatically breaking down extracellular DNA in the mucus, reducing its viscosity and improving lung function. This is achieved through its action as a biosynthetic form of the human enzyme deoxyribonuclease I (DNase I).",
      "system_answer": "Dornase alfa is primarily used in the treatment of cystic fibrosis.\n\nDornase alfa is an enzyme that helps to break down DNA in the mucus, reducing its viscosity and making it easier to clear from the lungs. This helps improve lung function and reduce the risk of respiratory infections in patients with cystic fibrosis.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [
        "General knowledge; specific sources could not be retrieved."
      ],
      "metrics": {
        "rouge1": 0.5599999999999999,
        "rouge2": 0.3469387755102041,
        "rougeL": 0.44000000000000006,
        "string_similarity": 0.4,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 22.480459928512573,
        "llm_correctness": 0.9,
        "inference_cost": 2.34064,
        "inference_tokens": 242596,
        "api_calls": 16,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 2.34064,
        "total_tokens": 242596,
        "api_calls": 16,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 2.33964,
            "tokens": 232596,
            "calls": 15
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 2.33964,
            "tokens": 232596,
            "calls": 15
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the mechanism of action of Cetuximab, and what is its primary target in humans?",
      "gt_answer": "Cetuximab functions by binding to the epidermal growth factor receptor (EGFR) in humans. This binding inhibits the receptor's activity, which is involved in the progression of certain types of cancer.",
      "system_answer": "Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR).\n\nCetuximab works by binding to the extracellular domain of the EGFR, thereby inhibiting the receptor",
      "gt_sources": [
        "None",
        "drugbank-targets"
      ],
      "system_sources": [
        "General scientific knowledge and literature on Cetuximab."
      ],
      "metrics": {
        "rouge1": 0.5423728813559322,
        "rouge2": 0.3508771929824561,
        "rougeL": 0.3728813559322034,
        "string_similarity": 0.3053435114503817,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 16.935328006744385,
        "llm_correctness": 1.0,
        "inference_cost": 0.97873,
        "inference_tokens": 106935,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.97873,
        "total_tokens": 106935,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.97773,
            "tokens": 96935,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.97773,
            "tokens": 96935,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "Which drug is produced using genetically modified Chinese hamster ovary (CHO) cells, and what is its primary use in clinical settings?",
      "gt_answer": "Dornase alfa is produced using genetically modified Chinese hamster ovary (CHO) cells through recombinant DNA technology. It is primarily used in clinical settings to reduce sputum viscosity in individuals with cystic fibrosis by enzymatically breaking down extracellular DNA.",
      "system_answer": "The specific drug produced using genetically modified CHO cells was not identified in the retrieved passages.\n\nThe passages retrieved mention various drugs and their interactions with CHO cells, such as Mitomycin C and its resistance in CHO cells, and the use of CHO cells in studies of other drugs like aripiprazole and irinotecan. However, none of these passages clearly identify a drug produced using genetically modified CHO cells.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [],
      "metrics": {
        "rouge1": 0.18867924528301885,
        "rouge2": 0.07692307692307691,
        "rougeL": 0.1509433962264151,
        "string_similarity": 0.03938115330520394,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 17.26248073577881,
        "llm_correctness": 0.0,
        "inference_cost": 1.08439,
        "inference_tokens": 117137,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 1.08439,
        "total_tokens": 117137,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 1.08339,
            "tokens": 107137,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 1.08339,
            "tokens": 107137,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "Describe the composition and production method of Etanercept and its therapeutic role.",
      "gt_answer": "Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. Etanercept is used therapeutically to interfere with tumor necrosis factor (TNF) activity, which plays a role in inflammatory and autoimmune diseases.",
      "system_answer": "Information on Etanercept composition, production, and therapeutic role not found in retrieved passages.\n\nThe retrieved passages focused on other drugs and did not provide relevant information about Etanercept.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [
        "No relevant sources found in the retrieved passages."
      ],
      "metrics": {
        "rouge1": 0.14285714285714288,
        "rouge2": 0.0,
        "rougeL": 0.10204081632653061,
        "string_similarity": 0.053175775480059084,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 18.656123876571655,
        "llm_correctness": 0.0,
        "inference_cost": 1.5019900000000002,
        "inference_tokens": 159057,
        "api_calls": 13,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 1.5019900000000002,
        "total_tokens": 159057,
        "api_calls": 13,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 1.50099,
            "tokens": 149057,
            "calls": 12
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 1.50099,
            "tokens": 149057,
            "calls": 12
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the unique structural characteristic of Lepirudin compared to natural hirudin, and when did its production cease?",
      "gt_answer": "Lepirudin is identical to natural hirudin except for the substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. The production of Lepirudin (Refludan) ceased on May 31, 2012.",
      "system_answer": "Information on Lepirudin not found\n\nThe searches did not yield information on the unique structural characteristic of Lepirudin compared to natural hirudin, nor when its production ceased.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [
        "No relevant sources found in the retrieved passages"
      ],
      "metrics": {
        "rouge1": 0.33333333333333337,
        "rouge2": 0.1142857142857143,
        "rougeL": 0.19444444444444445,
        "string_similarity": 0.07538802660753881,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 16.737492084503174,
        "llm_correctness": 0.0,
        "inference_cost": 0.78476,
        "inference_tokens": 87900,
        "api_calls": 7,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.78476,
        "total_tokens": 87900,
        "api_calls": 7,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.78376,
            "tokens": 77900,
            "calls": 6
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.78376,
            "tokens": 77900,
            "calls": 6
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the primary mechanism of action of Cetuximab?",
      "gt_answer": "Cetuximab targets the epidermal growth factor receptor (EGFR) in humans, where it binds to the N-terminal portion of the receptor, inhibiting its action.",
      "system_answer": "The primary mechanism of action of Cetuximab was not found in the retrieved passages.\n\nDespite multiple attempts to retrieve information, the passages did not contain details about Cetuximab. The passages retrieved were related to other drugs and mechanisms.",
      "gt_sources": [
        "None",
        "drugbank-targets"
      ],
      "system_sources": [],
      "metrics": {
        "rouge1": 0.2580645161290323,
        "rouge2": 0.0,
        "rougeL": 0.16129032258064516,
        "string_similarity": 0.2141119221411192,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 10.923943996429443,
        "llm_correctness": 0.0,
        "inference_cost": 0.5666199999999999,
        "inference_tokens": 65880,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.5666199999999999,
        "total_tokens": 65880,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.5656199999999999,
            "tokens": 55880,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.5656199999999999,
            "tokens": 55880,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the clinical use of Dornase alfa and its mechanism of action in cystic fibrosis patients?",
      "gt_answer": "Dornase alfa is used in cystic fibrosis patients to reduce sputum viscosity and viscoelasticity by enzymatically breaking down extracellular DNA released by degenerating leukocytes during inflammatory responses.",
      "system_answer": "Information on Dornase alfa in cystic fibrosis patients is not available in the retrieved passages.\n\nThe retrieved passages did not contain relevant information about the clinical use or mechanism of action of Dornase alfa in cystic fibrosis patients. The passages focused on other drugs and studies unrelated to the query.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [
        "No relevant sources found in the retrieved passages."
      ],
      "metrics": {
        "rouge1": 0.2597402597402597,
        "rouge2": 0.10666666666666666,
        "rougeL": 0.23376623376623376,
        "string_similarity": 0.0299625468164794,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 21.29502010345459,
        "llm_correctness": 0.0,
        "inference_cost": 0.9323199999999999,
        "inference_tokens": 102418,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.9323199999999999,
        "total_tokens": 102418,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.93132,
            "tokens": 92418,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.93132,
            "tokens": 92418,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "Which drug targets the Epidermal growth factor receptor (EGFR) and what is its known action?",
      "gt_answer": "Cetuximab targets the Epidermal growth factor receptor (EGFR) in humans, and its action is known.",
      "system_answer": "Erlotinib, gefitinib, and EKB-569 are drugs that target the Epidermal Growth Factor Receptor (EGFR).\n\nErlotinib and gefitinib are EGFR tyrosine kinase inhibitors used in the treatment of non-small-cell lung cancer and other cancers. Erlotinib is effective in reversing drug resistance mediated by certain transporters, while gefitinib is particularly effective in tumors with activating EGFR mutations. EKB-569 is a selective and irreversible inhibitor of EGFR being developed as an anticancer agent.",
      "gt_sources": [
        "None",
        "drugbank-targets"
      ],
      "system_sources": [],
      "metrics": {
        "rouge1": 0.2247191011235955,
        "rouge2": 0.13793103448275865,
        "rougeL": 0.2247191011235955,
        "string_similarity": 0.254606365159129,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 10.047935962677002,
        "llm_correctness": 0.5,
        "inference_cost": 0.10517000000000001,
        "inference_tokens": 19773,
        "api_calls": 4,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.10517000000000001,
        "total_tokens": 19773,
        "api_calls": 4,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.10417000000000001,
            "tokens": 9773,
            "calls": 3
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.10417000000000001,
            "tokens": 9773,
            "calls": 3
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "How is Etanercept produced and what is its composition?",
      "gt_answer": "Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.",
      "system_answer": "Information on Etanercept production and composition not found.\n\nThe retrieved passages did not contain relevant information about Etanercept. The passages were related to other drugs and their interactions or compositions.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [
        "No relevant sources found in the provided documents."
      ],
      "metrics": {
        "rouge1": 0.10126582278481011,
        "rouge2": 0.0,
        "rougeL": 0.10126582278481011,
        "string_similarity": 0.0074211502782931356,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 18.037534952163696,
        "llm_correctness": 0.0,
        "inference_cost": 0.7786299999999999,
        "inference_tokens": 86989,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.7786299999999999,
        "total_tokens": 86989,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.77763,
            "tokens": 76989,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.77763,
            "tokens": 76989,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the mechanism of action for Cetuximab, and under what brand name is it marketed?",
      "gt_answer": "Cetuximab is an epidermal growth factor receptor binding FAB, composed of variable regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr, with human IgG1 heavy and kappa light chain constant regions. It is marketed under the brand name Erbitux by Eli Lilly and Company.",
      "system_answer": "Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used in cancer treatment.\n\nCetuximab works by binding to the epidermal growth factor receptor (EGFR) on the surface of cancer cells, blocking the receptor and preventing the cancer cells from growing and dividing. It is commonly used in the treatment of certain types of head and neck cancers and colorectal cancer.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [
        "General knowledge and standard medical references."
      ],
      "metrics": {
        "rouge1": 0.375,
        "rouge2": 0.1272727272727273,
        "rougeL": 0.30357142857142855,
        "string_similarity": 0.1951219512195122,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 40.62395691871643,
        "llm_correctness": 0.7,
        "inference_cost": 5.380280000000001,
        "inference_tokens": 546470,
        "api_calls": 22,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 5.380280000000001,
        "total_tokens": 546470,
        "api_calls": 22,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 5.379280000000001,
            "tokens": 536470,
            "calls": 21
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 5.379280000000001,
            "tokens": 536470,
            "calls": 21
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the therapeutic use of Dornase alfa, and in what condition is it primarily used?",
      "gt_answer": "Dornase alfa is used to cleave extracellular DNA into 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products, thereby reducing sputum viscosity and viscoelasticity. It is primarily used in individuals with cystic fibrosis to manage the accumulation of extracellular DNA released by degenerating leukocytes during inflammatory responses to infections.",
      "system_answer": "Dornase alfa is primarily used in the treatment of cystic fibrosis.\n\nDornase alfa is an enzyme that helps to thin and loosen mucus in the airways, making it easier to cough up and clear the lungs. It is primarily used in patients with cystic fibrosis to improve lung function and reduce the risk of respiratory infections.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [
        "No specific source was retrieved from the database. This information is based on general medical knowledge."
      ],
      "metrics": {
        "rouge1": 0.4077669902912622,
        "rouge2": 0.1782178217821782,
        "rougeL": 0.3689320388349515,
        "string_similarity": 0.06442166910688141,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 13.947625875473022,
        "llm_correctness": 0.8,
        "inference_cost": 1.18364,
        "inference_tokens": 127582,
        "api_calls": 10,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 1.18364,
        "total_tokens": 127582,
        "api_calls": 10,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 1.18264,
            "tokens": 117582,
            "calls": 9
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 1.18264,
            "tokens": 117582,
            "calls": 9
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "How is Etanercept produced, and what is its structural composition?",
      "gt_answer": "Etanercept is produced using recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1, containing the CH2 domain, the CH3 domain, and hinge region, but not the CH1 domain of IgG1.",
      "system_answer": "Information on Etanercept production and structure not found.\n\nThe retrieved passages did not contain relevant information about Etanercept. They were related to other drugs and their interactions or compositions.",
      "gt_sources": [
        "None",
        "drugbank-drug"
      ],
      "system_sources": [
        "No relevant sources found in the retrieved passages."
      ],
      "metrics": {
        "rouge1": 0.12631578947368421,
        "rouge2": 0.0,
        "rougeL": 0.08421052631578949,
        "string_similarity": 0.0064,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 19.117393255233765,
        "llm_correctness": 0.0,
        "inference_cost": 1.3492700000000002,
        "inference_tokens": 143793,
        "api_calls": 13,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 1.3492700000000002,
        "total_tokens": 143793,
        "api_calls": 13,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 1.3482700000000003,
            "tokens": 133793,
            "calls": 12
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 1.3482700000000003,
            "tokens": 133793,
            "calls": 12
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    },
    {
      "question": "What is the FDA-approved formulation of Dornase alfa, and what is its primary use?",
      "gt_answer": "The FDA-approved formulations of Dornase alfa include Pulmozyme and Pulmozyme 1mg/ml. Dornase alfa is primarily used to reduce sputum viscosity in patients with cystic fibrosis.",
      "system_answer": "Information on Dornase alfa not found\n\nDespite multiple attempts, the relevant information about the FDA-approved formulation and primary use of Dornase alfa was not found in the retrieved passages.",
      "gt_sources": [
        "None",
        "drugbank-drug_mixtures"
      ],
      "system_sources": [
        "No relevant sources found in the retrieved passages"
      ],
      "metrics": {
        "rouge1": 0.4210526315789474,
        "rouge2": 0.21818181818181817,
        "rougeL": 0.28070175438596495,
        "string_similarity": 0.336,
        "source_precision": 0.0,
        "source_recall": 0.0,
        "source_f1": 0.0,
        "processing_time": 10.712505102157593,
        "llm_correctness": 0.0,
        "inference_cost": 0.66893,
        "inference_tokens": 76247,
        "api_calls": 7,
        "source_relevance_avg": 0.0,
        "source_relevance_max": 0.0
      },
      "cost_metrics": {
        "total_cost": 0.66893,
        "total_tokens": 76247,
        "api_calls": 7,
        "model_breakdown": {
          "text-embedding-ada-002": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "gpt-4o": {
            "cost": 0.66793,
            "tokens": 66247,
            "calls": 6
          }
        },
        "endpoint_breakdown": {
          "embedding": {
            "cost": 0.001,
            "tokens": 10000,
            "calls": 1
          },
          "chat.completions": {
            "cost": 0.66793,
            "tokens": 66247,
            "calls": 6
          }
        }
      },
      "source_relevance": {
        "average": 0.0,
        "maximum": 0.0
      }
    }
  ],
  "aggregate_metrics": {
    "rouge1": {
      "mean": 0.3290015043073362,
      "median": 0.3303030303030303,
      "min": 0.10126582278481011,
      "max": 0.5599999999999999,
      "std": 0.14950517288012743
    },
    "rouge2": {
      "mean": 0.1511078444643251,
      "median": 0.12077922077922079,
      "min": 0.0,
      "max": 0.39344262295081966,
      "std": 0.1261190877869029
    },
    "rougeL": {
      "mean": 0.2568933946863499,
      "median": 0.24415584415584418,
      "min": 0.08421052631578949,
      "max": 0.5396825396825397,
      "std": 0.12361204049086254
    },
    "string_similarity": {
      "mean": 0.1924989141266643,
      "median": 0.20461693668031572,
      "min": 0.0064,
      "max": 0.4909090909090909,
      "std": 0.15594694302601306
    },
    "source_precision": {
      "mean": 0.0,
      "median": 0.0,
      "min": 0.0,
      "max": 0.0,
      "std": 0.0
    },
    "source_recall": {
      "mean": 0.0,
      "median": 0.0,
      "min": 0.0,
      "max": 0.0,
      "std": 0.0
    },
    "source_f1": {
      "mean": 0.0,
      "median": 0.0,
      "min": 0.0,
      "max": 0.0,
      "std": 0.0
    },
    "llm_correctness": {
      "mean": 0.325,
      "median": 0.0,
      "min": 0.0,
      "max": 1.0,
      "std": 0.4097255178775176
    },
    "inference_cost": {
      "mean": 1.1969705000000002,
      "median": 0.955525,
      "min": 0.10517000000000001,
      "max": 5.380280000000001,
      "std": 1.0663716672036774
    },
    "inference_tokens": {
      "mean": 128711.35,
      "median": 104676.5,
      "min": 19773,
      "max": 546470,
      "std": 106460.17357597864
    },
    "api_calls": {
      "mean": 10.65,
      "median": 10.0,
      "min": 4,
      "max": 22,
      "std": 3.5815499438092444
    },
    "source_relevance_avg": {
      "mean": 0.0,
      "median": 0.0,
      "min": 0.0,
      "max": 0.0,
      "std": 0.0
    },
    "source_relevance_max": {
      "mean": 0.0,
      "median": 0.0,
      "min": 0.0,
      "max": 0.0,
      "std": 0.0
    }
  }
}